Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a clinical study titled ‘A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies.’ This study aims to assess the safety and effectiveness of ABBV-319 in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). The significance of this study lies in its potential to offer new treatment options for these aggressive and challenging cancers.
The intervention being tested is ABBV-319, an investigational drug administered intravenously. It is designed to treat patients with relapsed or refractory B-cell lymphomas, including DLBCL, FL, and CLL, by determining optimal dosing and assessing changes in disease activity.
The study is interventional and follows a non-randomized, sequential model with no masking. Its primary purpose is treatment, focusing on determining the safety and efficacy of ABBV-319 through dose escalation and expansion phases.
The study began on August 22, 2022, and is currently recruiting participants. The primary completion and estimated study completion dates are not specified, but the last update was submitted on August 25, 2025. These dates are crucial for tracking progress and potential market entry.
This study update could positively influence AbbVie’s stock performance and investor sentiment by demonstrating progress in developing a novel cancer treatment. It positions AbbVie competitively within the oncology sector, potentially impacting its market standing against other pharmaceutical companies.
The study is ongoing, with further details available on the ClinicalTrials portal.